CytomX Therapeutics (NASDAQ:CTMX) Upgraded by JPMorgan Chase & Co. to “Overweight” Rating

JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a neutral rating to an overweight rating in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The firm currently has $12.00 target price on the biotechnology company’s stock, up from their previous target price of $7.00.

Several other equities research analysts have also recently weighed in on the company. Barclays upped their price target on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Cantor Fitzgerald raised their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Piper Sandler boosted their target price on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $10.00 target price on shares of CytomX Therapeutics in a research report on Monday, March 9th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, CytomX Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $10.88.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX opened at $6.75 on Monday. The firm has a market capitalization of $1.14 billion, a P/E ratio of 16.88 and a beta of 2.44. The stock has a 50 day moving average price of $5.24 and a 200-day moving average price of $4.07. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $8.21.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC purchased a new position in CytomX Therapeutics during the second quarter valued at $19,208,000. Commodore Capital LP bought a new stake in CytomX Therapeutics in the second quarter worth $17,462,000. Perceptive Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the second quarter worth $15,876,000. Franklin Resources Inc. purchased a new stake in shares of CytomX Therapeutics in the second quarter worth $13,096,000. Finally, Vivo Capital LLC bought a new position in shares of CytomX Therapeutics during the second quarter valued at $13,096,000. Institutional investors own 67.77% of the company’s stock.

Key Stories Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 expansion data show solid activity in late‑line colorectal cancer — confirmed response rates of 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, estimated PFS ~7.1 months at the higher dose, and manageable safety with ongoing dose optimization. Management is targeting mid‑year FDA interactions to align on a potential registrational trial. Varsetatug Masetecan Continues to Demonstrate Positive Data
• Positive Sentiment: Analyst upgrades and higher price targets lifted sentiment — HC Wainwright raised its target to $17 (buy) and JPMorgan upgraded CTMX to overweight with a $12 target; Seeking Alpha and Benzinga published bullish takes tying valuation to Varseta‑M’s late‑line mCRC opportunity. These notes reinforced upside expectations. Mid‑Cap CytomX Therapeutics’ Colorectal Cancer Data Fuels Stock Rally
• Neutral Sentiment: Market reaction and high trading volume: CTMX experienced unusually heavy volume and a large pre‑market move as headlines circulated and investors digested the clinical readout plus analyst commentary. That amplifies intraday volatility but is informational rather than fundamental by itself. Why CTMX Stock Is Soaring Pre‑Market
• Negative Sentiment: Proposed $250M underwritten public offering of common stock and pre‑funded warrants — the financing will be dilutive and typically weighs on near‑term per‑share metrics despite extending the cash runway for development. CytomX Announces Proposed Public Offering
• Negative Sentiment: Q4 miss on EPS and revenue — CTMX reported a ($0.22) EPS vs. consensus (~$0.08 loss) and revenue well below estimates, reinforcing near‑term cash burn and highlighting the company remains pre‑commercial. These fundamentals contrast with the positive clinical news. CTMX Reports Q4 Loss, Misses Revenue Estimates

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.